Toxicology, Trauma and Medicine Group, Chemical, Biological & Radiological Division, Dstl Porton Down, Salisbury, SP4 0JQ, UK.
Chem Biol Interact. 2016 Nov 25;259(Pt B):175-181. doi: 10.1016/j.cbi.2016.04.038. Epub 2016 May 1.
The provision of effective Medical Countermeasures (MedCM) for all agents and routes of exposure is a strategic goal of defence research and development. In the case of military autoinjector-based therapies for nerve agent poisoning, current treatment effectiveness is limited by the oxime reactivator being effective against only certain agents, by rapid clearance times of the drugs and because the doses may not be optimal for treatment of severe poisoning. Prolonged poisoning by nerve agents entering the body through the skin is also challenging. Since casualty handling timelines have reduced significantly in recent years, it may be sufficient for first aid therapy to provide protection for only a few hours until further medical treatment is available. Therefore, the traditional evaluation of first aid therapy in animal models of survival at 24 h may not be appropriate. At various echelons of medical care, further therapeutic interventions are possible. The current basis for the medical management of nerve-agent poisoned casualties is derived mainly from clinical experience with pesticide poisoning. Adjunct therapy with a bioscavenger (such as human butyrylcholinesterase (huBChE)), could have utility as a delayed intervention by reducing the toxic load. It has previously been demonstrated that huBChE is an effective post-exposure therapy against percutaneous VX poisoning. It is recommended that the scope of animal models of nerve agent MedCM are extended to cover evaluation of both first aid MedCM over significantly reduced timescales, and subsequent supportive therapeutic and medical management strategies over longer timescales. In addition to bioscavengers, these strategies could include repeated combined and individual therapy drugs to alleviate symptoms, other classes of drugs or ventilatory support. Crown Copyright [2016] Published by Elsevier Ireland Ltd. This is an open access article under the Open Government Licence (OGL) (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).
为所有接触途径和接触物提供有效的医疗对策(MedCM)是国防研究与开发的战略目标。在军事自动注射器神经毒剂中毒治疗中,目前的治疗效果受到肟类再激活剂仅对某些特定毒剂有效的限制,药物清除速度快,并且由于剂量可能不是治疗严重中毒的最佳选择。通过皮肤进入人体的神经毒剂长时间中毒也是一个挑战。由于近年来伤员处理时间线大大缩短,急救治疗只需提供几个小时的保护,直到有进一步的医疗救助,因此,传统的动物模型 24 小时生存评估可能并不适合。在医疗护理的各个层面,都可以进行进一步的治疗干预。目前神经毒剂中毒伤员医疗管理的基础主要来自农药中毒的临床经验。生物清除剂(如人丁酰胆碱酯酶(huBChE))的辅助治疗可能具有延迟干预的作用,可以减少毒性负荷。先前已经证明 huBChE 是一种有效的经皮 VX 中毒后治疗方法。建议将神经毒剂医疗对策的动物模型范围扩大,以涵盖大大缩短时间范围内的急救医疗对策的评估,以及更长时间范围内的后续支持性治疗和医疗管理策略。除了生物清除剂外,这些策略还可以包括重复联合和个体化治疗药物以缓解症状,以及其他类别的药物或通气支持。[2016]版权所有,由爱思唯尔爱尔兰有限公司出版。这是一份在开放政府许可证(OGL)(http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/)下发布的开放获取文章。